Vanda Pharmaceuticals (VNDA) Misses Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts VNDA Hot Sheet
Join SI Premium – FREE
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q2 EPS of $0.03, $0.05 worse than the analyst estimate of $0.08. Revenue for the quarter came in at $46.06 million versus the consensus estimate of $62 million.
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
- InspireMD (NSPR) Tops Q2 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
